SYRE
Spyre Therapeutics Inc.
NASDAQ: SYRE · HEALTHCARE · BIOTECHNOLOGY
$71.89
+4.75% today
Updated 2026-04-29
Market cap
$6.20B
P/E ratio
—
P/S ratio
650.22x
EPS (TTM)
$-1.98
Dividend yield
—
52W range
$12 – $75
Volume
1.1M
Spyre Therapeutics Inc. (SYRE) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $6.08M | $4.63M | $5.21M | $3.89M | $0.00 | $0.00 | $18.74M | $2.33M | $886000.00 | $886000.00 | $0.00 |
| Revenue growth (YoY) | — | — | -23.9% | +12.5% | -25.3% | -100.0% | — | — | -87.6% | -62.0% | +0.0% | -100.0% |
| Cost of revenue | $19000.00 | $89000.00 | — | — | — | $901000.00 | $1.62M | $2.00M | $1.96M | $964000.00 | $964000.00 | $171.65M |
| Gross profit | $-19000.00 | $6.00M | $4.63M | $5.21M | $3.89M | $-901000.00 | $-1.62M | $18.74M | $2.33M | $-78000.00 | $886000.00 | $-171.65M |
| Gross margin | — | 98.5% | 100.0% | 100.0% | 100.0% | — | — | 100.0% | 100.0% | -8.8% | 100.0% | — |
| R&D | $6.83M | $11.45M | $18.14M | $22.82M | $36.72M | $64.60M | $59.64M | $57.07M | $58.58M | $89.50M | $162.79M | $171.65M |
| SG&A | — | $5.95M | — | — | — | $17.80M | $21.84M | $27.32M | $28.53M | $39.95M | $45.78M | $47.91M |
| Operating income | $-8.90M | $-11.31M | $-21.91M | $-27.68M | $-45.46M | $-80.33M | $-81.48M | $-65.65M | $-84.78M | $-242.30M | $-208.57M | $-209.56M |
| Operating margin | — | -185.9% | -473.3% | -531.7% | -1169.3% | — | — | -350.3% | -3640.2% | -27348.0% | -23540.2% | — |
| EBITDA | $-10.33M | $-11.23M | $-21.77M | $-27.43M | $-45.17M | $-77.35M | $-79.27M | $-64.07M | $-82.82M | $-242.30M | $-207.97M | $-209.56M |
| EBITDA margin | — | -184.5% | -470.5% | -526.9% | -1161.8% | — | — | -341.9% | -3555.9% | -27348.0% | -23472.6% | — |
| EBIT | $-10.35M | $-11.31M | $-21.91M | $-27.68M | $-45.46M | $-78.25M | $-80.89M | $-65.65M | $-84.78M | $-243.05M | $-128.56M | $-219.56M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-10.35M | $-11.29M | $-21.70M | $-27.24M | $-44.35M | $-78.25M | $-80.89M | $-65.80M | $-83.81M | $-338.79M | $-208.02M | $-155.20M |
| Net income growth (YoY) | — | -9.2% | -92.1% | -25.5% | -62.8% | -76.5% | -3.4% | +18.7% | -27.4% | -304.2% | +38.6% | +25.4% |
| Profit margin | — | -185.6% | -468.8% | -523.3% | -1140.6% | — | — | -351.1% | -3598.8% | -38238.1% | -23478.3% | — |